Cargando…

Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

BACKGROUND: The present study aimed to evaluate cardiometabolic risks [weight gain, blood lipid levels (total cholesterol and triglycerides), blood glucose levels, hemoglobin A(1c) (HbA(1c)) levels, and corrected QT interval (QTc) prolongation] associated with the use of blonanserin and perospirone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kishi, Taro, Matsuda, Yuki, Iwata, Nakao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913743/ https://www.ncbi.nlm.nih.gov/pubmed/24505373 http://dx.doi.org/10.1371/journal.pone.0088049

Ejemplares similares

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi, Taro, et al.
Publicado: (2014)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi, Taro, et al.
Publicado: (2016)

Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials
por: Kishi, Taro, et al.
Publicado: (2015)

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
por: Kishi, Taro, et al.
Publicado: (2014)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Oya, Kazuto, et al.
Publicado: (2015)

PM397. Effectiveness of blonanserin in patients with schizophrenia: A systematic review and meta-analysis of direct head-to-head comparisons with other antipsychotics
por: Kishi, T., et al.
Publicado: (2016)

Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis
por: Kishi, Taro, et al.
Publicado: (2018)

Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Okuyama, Yuji, et al.
Publicado: (2016)

Profile of blonanserin for the treatment of schizophrenia
por: Tenjin, Tomomi, et al.
Publicado: (2013)

Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials
por: Kishi, Taro, et al.
Publicado: (2020)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi, Taro, et al.
Publicado: (2017)

Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2015)

Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Deng, Shu-Wen, et al.
Publicado: (2023)

Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials
por: Kishi, Taro, et al.
Publicado: (2021)

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

A case of neuroleptic malignant syndrome induced by perospirone
por: Chen, Jing, et al.
Publicado: (2013)

Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2016)

Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta‐analysis of phase 3 trials in Japan
por: Kishi, Taro, et al.
Publicado: (2020)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
por: Iwata, Nakao, et al.
Publicado: (2019)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

S220. BLONANSERIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA – WHO IS BENEFITED FROM BLONANSERIN AUGMENTATION? AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER STUDY
por: Bahk, Won-Myong, et al.
Publicado: (2018)

PM423. Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study
por: Woo, Young Sup, et al.
Publicado: (2016)

Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis
por: Kishi, Taro, et al.
Publicado: (2019)

Perospirone augmentation of escitalopram in the treatment of an adolescent sophophobia (fear of learning) patient
por: Miyazaki, Kensuke
Publicado: (2022)

Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Genetic Polymorphisms in Dopamine- and Serotonin-Related Genes and Treatment Responses to Risperidone and Perospirone
por: Tsutsumi, Atsushi, et al.
Publicado: (2009)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
por: Kishi, Taro, et al.
Publicado: (2019)

PT592. Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-analysis
por: Matsunaga, Shinji, et al.
Publicado: (2016)

Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression
por: Kishi, Taro, et al.
Publicado: (2022)

Melatonin receptor agonists—ramelteon and melatonin—for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2019)

Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2019)

A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch
por: Hagikura, Minako, et al.
Publicado: (2023)

Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
por: Kishi, Taro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d5de7dbkr1tmedn96eq8d149ul